3 reasons to keep holding your Cochlear Limited shares

Two hearing devices on the market now may help turn around revenue, making a potential buying opportunity.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The start of 2014 was not that good for shares in Cochlear Limited (ASX: COH) as the stock hit lows of about $52 in February.  The company, which is famous for its bionic hearing devices around the world, reported its first-half results of net profit down 73%.

Since then, the stock is up about 20% versus the 4% rise of the S&P ASX 200 Index (ASX: ^XJO). Setbacks in 2011 affected the business until this year, but it looks like things are improving. That can be seen by the share price recovery, but I know of three reasons why shareholders should keep holding onto their shares because bigger gains are possible.

Latest Cochlear devices on the market

Earlier this year the product that had failure problems in 2011 was certified to return to market in Europe after manufacturing issues were solved. Along with that, the company's Nucleus Hybrid device was also approved for sale in the US. With two separate implants on the market, full year revenue is expected to rise about 13% in 2014-2015.

That's good because FY 2014 interim net profit was way down. The stock was punished twice in early and mid-2013 when two earnings downgrades were released. The share price was down from $80 to about $55. Since early May this year, it has recovered to about $62.45, but I think offloading shares now may be premature.

Strong quality company at low prices

Good companies can occasionally have bad half years or years when problems pull down earnings, but in this case it was a temporary problem that allowed long-term investors to buy into a quality stock at more affordable prices.

Cochlear regularly has high net profit margins and return on equity. Its specialised medical products command premium prices and are in high demand, so it has good competitive advantages. The 2011 problem interrupted business and earnings growth, but now it can get back on track with this year's advances.

Dividend history, yield and growth

Another great thing about Cochlear is the past 10-year record of increased dividends every year. Even in 2011 and 2012 when earnings fell due to the defective device issue, dividends rose. Steady shareholders picked up cheaper shares and received higher dividends. It still has an attractive 4.0% yield partially franked. Now may be the time when earnings begin to recover. That could increase the dividend payout more. The company is definitely a good portfolio candidate for the long term.

Motley Fool contributor Darryl Daté-Shappard does not own shares in any company mentioned. 

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »